Drugs / Bacillus Calmette-Guerin (BCG)
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02326168 | Oct 2013 → Oct 2015 | urinary bladder cancer | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03317158 | Nov 2017 → Dec 2028 expected | urinary bladder cancer, urothelial carcinoma | Noah Hahn, M.D. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04507126 | Mar 2021 → Dec 2022 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT02075203 Comparator | Feb 2014 → Aug 2017 | tuberculosis | Aeras | Completed | Missed primary |
| Phase 3 | NCT04149574 Background | Jan 2020 → Oct 2023 | urinary bladder neoplasm | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT06767982 Comparator | Jan 2019 → Dec 2022 | non-invasive bladder urothelial carcinoma | Ankara University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bacillus Calmette-Guerin (BCG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04507126 ↗ |
| Modality | Vaccine | “Both the BCG and H4:IC31 vaccines were immunogenic.” PMID 29996082 ↗ Jul 2018 |
| Route | Other | “intravesical therapy” NCT06767982 ↗ |